$1.9 Billion is the total value of Camber Capital Management LP's 34 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 41.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | Sell | ALLERGAN PLC | $168,290,000 | -19.6% | 1,000,000 | -20.0% | 8.85% | -9.3% |
| MYL | Sell | MYLAN N V | $168,130,000 | -4.5% | 8,500,000 | -8.1% | 8.84% | +7.7% |
| PRGO | Sell | PERRIGO CO PLC | $95,013,000 | -0.2% | 1,700,000 | -15.0% | 5.00% | +12.5% |
| BKD | BROOKDALE SENIOR LIVING | $94,750,000 | +5.1% | 12,500,000 | 0.0% | 4.98% | +18.6% | |
| DVA | Sell | DAVITA INC | $85,605,000 | -23.9% | 1,500,000 | -25.0% | 4.50% | -14.2% |
| AGN | ALLERGAN PLCcall | $84,145,000 | +0.5% | 500,000 | 0.0% | 4.42% | +13.4% | |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $83,249,000 | +58.9% | 850,000 | +112.5% | 4.38% | +79.3% |
| BIIB | New | BIOGEN INC | $81,487,000 | – | 350,000 | +100.0% | 4.28% | – |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $76,065,000 | +67.7% | 1,500,000 | +50.0% | 4.00% | +89.2% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $74,375,000 | -12.2% | 500,000 | -23.1% | 3.91% | -1.0% |
| HCA | HCA HEALTHCARE INC | $72,252,000 | -10.9% | 600,000 | 0.0% | 3.80% | +0.5% | |
| THC | Buy | TENET HEALTHCARE CORP | $69,678,000 | +34.9% | 3,150,000 | +26.0% | 3.66% | +52.2% |
| ALKS | Buy | ALKERMES PLC | $68,285,000 | +1509.0% | 3,500,000 | +1758.9% | 3.59% | +1713.6% |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $62,608,000 | -16.4% | 650,000 | 0.0% | 3.29% | -5.6% | |
| MYL | MYLAN N Vcall | $59,340,000 | +3.9% | 3,000,000 | 0.0% | 3.12% | +17.2% | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $56,490,000 | -25.6% | 750,000 | +50.0% | 2.97% | -16.1% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $54,645,000 | -38.6% | 3,000,000 | +20.0% | 2.87% | -30.7% |
| AMAG | Buy | AMAG PHARMACEUTICALS INC | $50,705,000 | +69.2% | 4,390,000 | +46.3% | 2.67% | +90.8% |
| MNTA | MOMENTA PHARMACEUTICALS INC | $45,360,000 | +4.1% | 3,500,000 | 0.0% | 2.38% | +17.4% | |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $41,654,000 | +3.6% | 2,950,000 | +47.5% | 2.19% | +16.8% |
| ABBV | New | ABBVIE INC | $37,860,000 | – | 500,000 | +100.0% | 1.99% | – |
| ZYME | Sell | ZYMEWORKS INC | $37,200,000 | -35.0% | 1,500,000 | -42.3% | 1.96% | -26.6% |
| NVO | New | NOVO-NORDISK A Sadr | $36,190,000 | – | 700,000 | +100.0% | 1.90% | – |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $31,900,000 | +11.2% | 400,000 | +8.8% | 1.68% | +25.4% |
| THOR | SYNTHORX INC | $30,297,000 | +20.4% | 1,862,116 | 0.0% | 1.59% | +35.8% | |
| MYGN | New | MYRIAD GENETICS INC | $28,630,000 | – | 1,000,000 | +100.0% | 1.51% | – |
| CYCN | Buy | CYCLERION THERAPEUTICS INC | $26,992,000 | +50.9% | 2,227,052 | +42.6% | 1.42% | +70.1% |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $21,340,000 | +6.6% | 500,000 | 0.0% | 1.12% | +20.3% | |
| WMGI | New | WRIGHT MED GROUP N V | $15,473,000 | – | 750,000 | +100.0% | 0.81% | – |
| GLYC | New | GLYCOMIMETICS INC | $15,085,000 | – | 3,500,000 | +100.0% | 0.79% | – |
| TBIO | New | TRANSLATE BIO INC | $14,865,000 | – | 1,500,000 | +100.0% | 0.78% | – |
| AVRO | New | AVROBIO INC | $7,060,000 | – | 500,000 | +100.0% | 0.37% | – |
| STRO | SUTRO BIOPHARMA INC | $5,454,000 | -20.1% | 600,000 | 0.0% | 0.29% | -9.7% | |
| SGRY | SURGERY PARTNERS INC | $1,182,000 | -9.3% | 160,084 | 0.0% | 0.06% | +1.6% | |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.40% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $0 | – | -6,500,000 | -100.0% | -2.80% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -1,700,000 | -100.0% | -2.89% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -1,000,000 | -100.0% | -3.15% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -1,000,000 | -100.0% | -13.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.